Xencor Inc - ESG Rating & Company Profile powered by AI
Comprehensive Sustainability assessment of Xencor Inc can be accessed by signing up for free. The ESG assessment for Xencor Inc represents its reporting of the UN SDGs. The ESG rating includes 17 United Nations Sustainable Development Goals including: 'Gender Equality', 'Industry, Innovation & Infrastructure' and 'Peace, Justice & Strong Institutions'.
Xencor Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 1.6 and governance score of 6.4.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
| 989 | Tricida Inc | 4.1 | High |
| 1004 | Xencor Inc | 4.0 | High |
| 1004 | Can B Corp | 4.0 | High |
| 1004 | CLS Holdings USA Inc | 4.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Xencor Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Xencor Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Xencor Inc report the average age of the workforce?
Sign up for free to unlockDoes Xencor Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Xencor Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Xencor Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Xencor Inc offer flexible work?
Sign up for free to unlockDoes Xencor Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Xencor Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Xencor Inc conduct supply chain audits?
Sign up for free to unlockDoes Xencor Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Xencor Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Xencor Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Xencor Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Xencor Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Xencor Inc disclose water use targets?
Sign up for free to unlockDoes Xencor Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Xencor Inc have a product recall in the last two years?
Sign up for free to unlockDoes Xencor Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Xencor Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Xencor Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Xencor Inc disclose parental leave metrics?
Sign up for free to unlockDoes Xencor Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Xencor Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Xencor Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Xencor Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Xencor Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Xencor Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Xencor Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Xencor Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Xencor Inc disclose its waste policy?
Sign up for free to unlockDoes Xencor Inc report according to TCFD requirements?
Sign up for free to unlockDoes Xencor Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Xencor Inc disclose energy use targets?
Sign up for free to unlockDoes Xencor Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Xencor Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Xencor Inc
These potential risks are based on the size, segment and geographies of the company.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.